Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.
HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.
A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.
A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.
This is according to a recent survey of gay and bi men taking daily Truvada as PrEP.
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
A trial of long-acting cabotegravir given every eight weeks found that it yielded adequate drug levels and was well tolerated.
Cabotegravir and rilpivirine combo shows promise as well-tolerated and effective antiretroviral regimen in a trial.
The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.
Phase III trial begins for long-acting injectable form of the experimental antiretroviral cabotegravir for use as PrEP against HIV.
A long-acting injectable HIV regimen dosed every four weeks is slated to advance to Phase III trials in late 2016.
“We need drugs that are gentler, kinder, better and cheaper.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.